Skip to main content

$3.18 0.09 (2.91%)










30 June 2023 at 4:12pm
Register to track HLS and receive email alerts.

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.

Expand Company Description

Market Cap (24-Feb)

$998,342,144 (160th)

Close (30-Jun)


Volume (30-Jun)


Shortsold (13-Feb)

22,310,665 (3.07%) (65th)

52w High


52w Low






[ARTICLE] Why it’s so hard to make money from blood tests

A news article has been posted about Healius on the AFR. The article was published around , on 3 December 2023 at 1:57pm.

There’s restructuring ahead at the No. 2 pathology provider Healius, which despite its activist ructions, has yielded a 30 per cent return since its 2023 low.

Read Article

HLS was $3.18 at the close of trade on 30 June 2023

Find all articles about Healius, including others on the AFR, on the media page.

You must login or register to post a comment.

You must be logged in to post a reply.

Register to track HLS and receive email alerts.